Muscle Wasting Disorders - Pipeline Review, H1 2012
Global Markets Direct
January 23, 2012 117 Pages - SKU: GMD6775925
|
|
Muscle Wasting Disorders - Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Muscle Wasting Disorders - Pipeline Review, H1 2012', provides an overview of the Muscle Wasting Disorders therapeutic pipeline. This report provides information on the therapeutic development for Muscle Wasting Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Muscle Wasting Disorders. 'Muscle Wasting Disorders - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Muscle Wasting Disorders.
- A review of the Muscle Wasting Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Muscle Wasting Disorders pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Muscle Wasting Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Muscle Wasting Disorders pipeline depth and focus of Muscle Wasting Disorders therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
|
- Introduction
- Global Markets Direct Report Coverage
- Muscle Wasting Disorders Overview
- Therapeutics Development
- An Overview of Pipeline Products for Muscle Wasting Disorders
- Muscle Wasting Disorders Therapeutics under Development by Companies
- Muscle Wasting Disorders Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Muscle Wasting Disorders Therapeutics - Products under Development by Companies
- Muscle Wasting Disorders Therapeutics - Products under Investigation by Universities/Institutes
- Companies Involved in Muscle Wasting Disorders Therapeutics Development
- Bristol-Myers Squibb Company
- Amgen Inc.
- Eli Lilly and Company
- BioLineRx, Ltd.
- Novartis AG
- Aphios Corporation
- GTx, Inc.
- Rigel Pharmaceuticals, Inc.
- AEterna Zentaris Inc.
- Ligand Pharmaceuticals Incorporated
- Palatin Technologies, Inc.
- Boryung Pharmaceutical Co., Ltd.
- Galapagos NV
- Asubio Pharmaceuticals, Inc.
- Helsinn Healthcare S.A.
- NovImmune SA
- KangLaiTe USA
- Vicus Therapeutics, LLC
- OHR Pharmaceutical Inc.
- Acacia Pharma Ltd.
- Rhythm Pharmaceuticals
- Muscle Wasting Disorders - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- SUN11031 - Drug Profile
- AEZS-130 - Drug Profile
- AMG 745 - Drug Profile
- Ostarine - Drug Profile
- RM-131 - Drug Profile
- BL-5040 - Drug Profile
- NI-1201 - Drug Profile
- Delta 9-THC - Drug Profile
- Delta 9-THCA - Drug Profile
- BMS-945429 - Drug Profile
- LGD-4033 - Drug Profile
- Kanglaite - Drug Profile
- GLPG0492 - Drug Profile
- Ghrelin - Drug Profile
- Enbrel - Drug Profile
- Anamorelin - Drug Profile
- APD209 - Drug Profile
- BL-6020 - Drug Profile
- Testosterone - Drug Profile
- Testosterone + Finasteride - Drug Profile
- Finasteride - Drug Profile
- Testosterone - Drug Profile
- VT-122 - Drug Profile
- ACVR 2Beta - Drug Profile
- OHR/AVR118 - Drug Profile
- VT-122 + Nexavar - Drug Profile
- MT-102 - Drug Profile
- Revlimid - Drug Profile
- LY2495655 - Drug Profile
- UX001 - Drug Profile
- BYM338 - Drug Profile
- Megace F - Drug Profile
- Drug For Cachexia - Drug Profile
- Drug For Cancer Cachexia - Drug Profile
- Muscle Wasting Disorders Therapeutics - Drug Profile Updates
- Muscle Wasting Disorders Therapeutics - Discontinued Products
- Muscle Wasting Disorders Therapeutics - Dormant Products
- Muscle Wasting Disorders - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Muscle Wasting Disorders, H1 2012
- Products under Development for Muscle Wasting Disorders - Comparative Analysis, H1 2012
- Number of Products under Development by Companies, H1 2012
- Number of Products under Development by Companies, H1 2012 (Contd..1)
- Number of Products under Investigation by Universities/Institutes, H1 2012
- Comparative Analysis by Late Stage Development, H1 2012
- Comparative Analysis by Mid Clinical Stage Development, H1 2012
- Comparative Analysis by Early Clinical Stage Development, H1 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
- Products under Development by Companies, H1 2012
- Products under Development by Companies, H1 2012 (Contd..1)
- Products under Investigation by Universities/Institutes, H1 2012
- Bristol-Myers Squibb Company, H1 2012
- Amgen Inc., H1 2012
- Eli Lilly and Company, H1 2012
- BioLineRx, Ltd., H1 2012
- Novartis AG, H1 2012
- Aphios Corporation, H1 2012
- GTx, Inc., H1 2012
- Rigel Pharmaceuticals, Inc., H1 2012
- AEterna Zentaris Inc., H1 2012
- Ligand Pharmaceuticals Incorporated, H1 2012
- Palatin Technologies, Inc., H1 2012
- Boryung Pharmaceutical Co., Ltd., H1 2012
- Galapagos NV, H1 2012
- Asubio Pharmaceuticals, Inc., H1 2012
- Helsinn Healthcare S.A., H1 2012
- NovImmune SA, H1 2012
- KangLaiTe USA, H1 2012
- Vicus Therapeutics, LLC, H1 2012
- OHR Pharmaceutical Inc., H1 2012
- Acacia Pharma Ltd., H1 2012
- Rhythm Pharmaceuticals, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Muscle Wasting Disorders Therapeutics - Drug Profile Updates
- Muscle Wasting Disorders Therapeutics - Discontinued Products
- Muscle Wasting Disorders Therapeutics - Dormant Products
- Muscle Wasting Disorders Therapeutics - Dormant Products (Contd..1)
- Muscle Wasting Disorders Therapeutics - Dormant Products (Contd..2)
- List of Figures
- Number of Products under Development for Muscle Wasting Disorders, H1 2012
- Products under Development for Muscle Wasting Disorders - Comparative Analysis, H1 2012
- Products under Development by Companies, H1 2012
- Products under Investigation by Universities/Institutes, H1 2012
- Late Stage Products, H1 2012
- Mid Clinical Stage Products, H1 2012
- Early Clinical Stage Products, H1 2012
- Discovery and Pre-Clinical Stage Products, H1 2012
- Assessment by Monotherapy Products, H1 2012
- Assessment by Combination Products, H1 2012
- Assessment by Route of Administration, H1 2012
- Assessment by Stage and Route of Administration, H1 2012
- Assessment by Molecule Type, H1 2012
- Assessment by Stage and Molecule Type, H1 2012
Share this report
Other tasks Related Markets Drug Discovery Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
